Pre-made Ivuxolimab benchmark antibody ( Whole mAb, anti-TNFRSF4 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-285
Anti-TNFRSF4 therapeutic antibody (Pre-made Ivuxolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ivuxolimab (also known as PF 4518600 or PF 8600) is an OX40 receptor agonist, as an intravenous therapy for solid tumours is in development with Pfizer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFRSF4 therapeutic antibody (Pre-made Ivuxolimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Pfizer;Dana-Farber Cancer Institute;M. D. Anderson Cancer Center;National Cancer Institute USA;University of Southern California|
|Conditions Active||Breast cancer;Renal cell carcinoma;Solid tumours;Acute myeloid leukaemia;Squamous cell cancer;Follicular lymphoma|